Companies › DexCom
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Insulin Glargine Insulin receptor agonist | INSR | Phase 1 | Type 2 Diabetes | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07681375 | Insulin Glargine | Phase 1 | Type 2 Diabetes | Metabolic and endocrine | Jan 2027 |
Cash of $961m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Sling Therapeutics Novo Nordisk Gan & Lee Pharmaceuticals. Sanofi Mannkind Gilead Sciences
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.